Position in ATAI
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$6,307,228
New position
Shares Held
1,781,703
first reported quarter
Ownership
0.484%
of shares outstanding
% of Portfolio
0.70%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Newtyn Management, LLC holds $110,545,509 across 7 Biotechnology names. ATAI ranks #4 (5.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TBPH |
Theravance Biopharma, Inc.
|
4,841,629 | $78,579,638 | |
| 2 | RCKT |
Rocket Pharmaceuticals, Inc.
|
3,165,900 | $11,333,922 | |
| 3 | RARE |
Ultragenyx Pharmaceutical Inc.
|
400,000 | $8,380,000 | |
| 4 | ATAI |
AtaiBeckley Inc.
This page
|
1,781,703 | $6,307,228 | |
| 5 | MREO |
Mereo BioPharma Group plc
|
7,079,056 | $2,336,088 | |
| 6 | WVE |
Wave Life Sciences Ltd.
|
300,000 | $2,175,000 | |
| 7 | QURE |
uniQure N.V.
|
87,684 | $1,433,633 |
All Filings in ATAI
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,307,228 | 1,781,703 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||